ACRV - Acrivon Therapeutics, Inc.
IEX Last Trade
6.12
-0.120 -1.961%
Share volume: 1
Last Updated: Thu 26 Dec 2024 03:11:29 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
3.82%
PREVIOUS CLOSE
CHG
CHG%
$6.24
-0.12
-1.92%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
-7.15%
1 Month
-12.99%
3 Months
-13.11%
6 Months
2.81%
1 Year
24.85%
2 Year
-46.52%
Key data
Stock price
$6.12
DAY RANGE
$6.24 - $6.24
52 WEEK RANGE
$3.65 - $11.90
52 WEEK CHANGE
$24.35
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Peter Blume-Jensen
Region: US
Website: acrivon.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: acrivon.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
We are a clinical stage biopharmaceutical company developing precision oncology medicines that we match to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing our proprietary proteomics-based patient responder identification platform. We were incorporated under the laws of the State of Delaware in March 2018. Our principal executive offices are located at 480 Arsenal Way, Suite 100, Watertown, Massachusetts.
Recent news